Zeynep Eroglu
Moffitt Cancer Center · SWOG Cancer Research Network · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zeynep Eroglu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07930182 · Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringH. Lee Moffitt Cancer Center and Research Institute · recruiting · Melanoma · principal investigator
- Early Ph1NCT05651828 · Adaptive Therapy of Vismodegib in Advanced Basal Cell CarcinomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Advanced Basal Cell Carcinoma · principal investigator
- Ph2NCT05070403 · Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Squamous Cell Carcinoma · principal investigator
- Ph2NCT04996823 · Axitinib + Ipilimumab in Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Melanoma · principal investigator
- Early Ph1NCT04741997 · Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation · principal investigator
- Ph2NCT04511013 · A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesSWOG Cancer Research Network · recruiting · Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma · principal investigator
- Early Ph1NCT03543969 · Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Melanoma (Skin), Skin Cancer, Skin Melanoma · principal investigator
- Ph1NCT03501368 · Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma, Unresectable Melanoma, Advanced Melanoma · principal investigator
- Ph1NCT02721459 · XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Melanoma, Skin Cancer · principal investigator
- Ph1NCT01657591 · Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT04511013
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:10 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.Lancet Oncol · 2021244 citationsRCR 14.3
- Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.J Clin Oncol · 2018186 citationsRCR 6.1
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.J Clin Oncol · 2021184 citationsRCR 8.3
- Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.Nat Med · 2023167 citationsRCR 11.7
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.Eur J Cancer · 2017163 citationsRCR 4.3
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.J Clin Oncol · 2020148 citationsRCR 5.2
- 127 citationsRCR 8.2
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.Cancer Discov · 2022114 citationsRCR 6.3
- Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.Ann Oncol · 202189 citationsRCR 3.8
- Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.Clin Cancer Res · 201865 citationsRCR 2.2